Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2012

View Archived Issues

Advanced Cancer Therapeutics receives NIH grant to develop novel agent for brain cancer

Specialised Therapeutics Australia in-licenses rights to anamorelin

Probiodrug discloses novel glutaminyl cyclase inhibitors

Chinese researchers disclose new PAF acetylhydrolase inhibitors

Eternity Bioscience patents novel PARP-1 inhibitors

Teijin Pharma presents novel CaSR antagonists with promising in vivo activity

NKTR-171 demonstrates efficacy in animal models of neuropathic pain

Grindeks discloses single enantiomer for cognitive disorders

Eli Lilly reports phase III data for ramucirumab in gastric cancer

New CCR2 receptor antagonists presented by Merck & Co.

Octahydrogenacridine succinate shows promising pharmacokinetics in healthy Chinese subjects

Idera Pharmaceuticals completes patient enrollment in phase II IMO-3100 trial

Researchers at Reata Pharmaceuticals prepare new NO production inhibitors

FDA accepts Serada NDA for filing

FDA grants Meridian Laboratories pre-IND meeting for ML-061

Tasimelteon restores cortisol rhythms in blind patients

Enrollment of fifth patient in ibrutinib trial triggers milestone payment

Novavax begins phase I trial of RSV vaccine candidate in older subjects

Endoribonuclease Dicer may be a marker for multiple sclerosis

Novo Nordisk submits U.S. and E.U. applications for turoctocog alfa

BioDelivery Sciences will launch Breakyl in the E.U.

FDA approves expanded indication for Actemra

Onyx Pharmaceuticals completes enrollment in phase III FOCUS trial

Abbott discloses initial results from phase IIb study of interferon-free HCV treatment regimen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...